Carbonic anhydrase IX (CA IX)
Carbonic anhydrase 9 (CA9), also known as Carbonic anhydrase (CA) IX, is a membrane-associated enzyme in the Carbonic anhydrase (CA) family.
Carbonic anhydrase 9 (CA9), also known as Carbonic anhydrase (CA) IX, is a membrane-associated enzyme in the Carbonic anhydrase (CA) family. It is widely recognized as a hypoxia-associated marker and a cancer-relevant protein because of its role in regulating tumor pH and supporting survival in low-Oxygen microenvironments. By contributing to acid–base balance at the cell surface, CA9 can help tumor cells adapt to hypoxia, promote aggressive behavior, and influence response to therapy.
In biomedical research, CA9 is studied both as a biomarker and as a therapeutic target. Its expression is often linked to invasive phenotypes and treatment resistance in solid tumors, including renal cell carcinoma, triple-negative breast cancer, anal squamous cell carcinoma, and other malignancies such as colorectal, head/neck, melanoma, and prostate tumors. Because of its tumor-associated expression pattern, CA9 has also been explored for molecular imaging and for selective inhibition strategies, including combinations with other cancer-associated enzymes such as Carbonic anhydrase (CA) XII.
Where the papers sit
8 papers from the last 6 months study Carbonic anhydrase IX (CA IX) directly · updated from PubMed 6 Nov 2026
Study type 0 clinical trials · 1 observational · 1 human data · 6 preclinical
Themes no clear themes
Those 8 do not share a common subject.
-
Cancer-focused work here ranges from plant-derived compounds and enzyme inhibitors to CAIX-targeted imaging and radiotherapy. The studies address gastric, pancreatic, renal, hepatic and pediatric brain tumours, using distinct molecular and diagnostic endpoints. Glycolysis, AKT-mTOR signalling, alkaliptosis, immune biomarkers and stromal barriers recur only in subsets. No shared therapeutic direction emerges beyond exploratory investigation of cancer biology and treatment.
Papers
The 8 papers from the last 6 months that study Carbonic anhydrase IX (CA IX) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (8)
- LC-MS/MS-Based Phytochemical Characterization of Cakile maritima Methanol Extract and Its Photodynamic Anticancer Activity in Gastric Cancer Cells. Rapid communications in mass spectrometry : RCM · 21 Jul 2026 PMID 42479944
- "Alkaline-Hammer Strategy" Breaks Acidic and Stromal Barriers to Induce Alkaliptosis and Enhance Immunotherapy in Pancreatic Cancer. Angewandte Chemie (International ed. in English) · 15 Jul 2026 PMID 42454703
- Development of a Novel 68Ga-Labeled Radiotracer Targeting Carbonic Anhydrase IX for the Diagnosis of Clear Cell Renal Cell Carcinoma. Molecular pharmaceutics · 13 Jul 2026 PMID 42439293
- Investigating the Inhibitory Properties of Diazo and Pyrazole-Carboxamide-Linked Benzenesulfonamides Against Carbonic Anhydrase Isoforms I, II, IX, and XII. ChemMedChem · 7 Jul 2026 PMID 42410713
- Valorization of Moringa oleifera pericarp via semi-synthetic sugar-based enone derivatives with anticancer potential: phytochemical isolation, cytotoxic evaluation, and dual EGFR/CAIX targeting. Scientific reports · 4 Jul 2026 PMID 42401652
- PEG4-Modified FAP-CAIX Heterodimeric Radioligand for Precision Imaging and Radiotherapy. Journal of medicinal chemistry · 29 Jun 2026 PMID 42367011
- Expression patterns of carbonic anhydrase IX and immune response biomarkers in pediatric gliomas and glioneuronal tumors. Journal of neuro-oncology · 24 Jun 2026 PMID 42340514
- Exploration of the Key Mechanism by Which Kaempferol Inhibits Glycolysis in Hepatocellular Carcinoma Cells via the AKT-mTOR Pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 20 Jun 2026 PMID 42322592
By study type
Observational studies and case reports (1)
- Expression patterns of carbonic anhydrase IX and immune response biomarkers in pediatric gliomas and glioneuronal tumors. Journal of neuro-oncology · 24 Jun 2026 PMID 42340514
Human data, design not indexed (1)
- Valorization of Moringa oleifera pericarp via semi-synthetic sugar-based enone derivatives with anticancer potential: phytochemical isolation, cytotoxic evaluation, and dual EGFR/CAIX targeting. Scientific reports · 4 Jul 2026 PMID 42401652
Preclinical: animal, cell and lab studies (6)
- LC-MS/MS-Based Phytochemical Characterization of Cakile maritima Methanol Extract and Its Photodynamic Anticancer Activity in Gastric Cancer Cells. Rapid communications in mass spectrometry : RCM · 21 Jul 2026 PMID 42479944
- "Alkaline-Hammer Strategy" Breaks Acidic and Stromal Barriers to Induce Alkaliptosis and Enhance Immunotherapy in Pancreatic Cancer. Angewandte Chemie (International ed. in English) · 15 Jul 2026 PMID 42454703
- Development of a Novel 68Ga-Labeled Radiotracer Targeting Carbonic Anhydrase IX for the Diagnosis of Clear Cell Renal Cell Carcinoma. Molecular pharmaceutics · 13 Jul 2026 PMID 42439293
- Investigating the Inhibitory Properties of Diazo and Pyrazole-Carboxamide-Linked Benzenesulfonamides Against Carbonic Anhydrase Isoforms I, II, IX, and XII. ChemMedChem · 7 Jul 2026 PMID 42410713
- PEG4-Modified FAP-CAIX Heterodimeric Radioligand for Precision Imaging and Radiotherapy. Journal of medicinal chemistry · 29 Jun 2026 PMID 42367011
- Exploration of the Key Mechanism by Which Kaempferol Inhibits Glycolysis in Hepatocellular Carcinoma Cells via the AKT-mTOR Pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 20 Jun 2026 PMID 42322592
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.